Correlation of abnormal histology with endoscopic findings among mycophenolate mofetil treated patients

Table 1 Demographic of mycophenolate mofetil treated patients and procedures (170 patients, 184 procedures) (%)

Characteristic
mean age	57.05
Female	89 (48.4)
Indication for procedure2
Screening	72 (39.1)
Diarrhea	51 (27.7)
Bleeding	24 (13.0)
Anemia	20 (10.9)
Abdominal pain	14 (7.7)
Constipation	3 (1.6)
Weight loss	3 (1.6)
Abnormal imaging	3 (1.6)
Bloating	1 (0.52)
Other (history of IBD, amyloid, stricture)	9 (4.9)
Indication for MMF
Organ transplant (kidney, liver, lung)	116
Autoimmune	35
Blood disorder	7
Unknown indication	26
Abnormal mucosa (gross)	40
With normal biopsies	10
With abnormal biopsies	25 (2 duplicates)
Without biopsies1	5
Normal mucosa (gross)	144
With normal biopsies	44 (normal biopsy or polypectomy, 1 for mass)
With abnormal biopsies	17 (1 duplicate)
Without biopsies1	83

¹Without biopsies done or with reports unavailable;

²Some procedures with multiple indications documented. MMF: Mycophenolate mofetil; IBD: Inflammatory bowel disease.

Table 2 Demographic of colitis among mycophenolate mofetil treated patients n (%)

Characteristic
n	39
mean age	51.44
Female	20 (51.3)
Indication for procedure
Diarrhea	28 (71.8)
Bleeding	2 (5.1)
Anemia	1 (2.6)
Screening	4 (10.3)
Abnormal imaging	2 (5.1)
Other (history of IBD)	2 (5.1)
Indication for MMF
Organ transplant	28 (71.8)
Autoimmune	4 (10.3)
Blood disorder	7 (17.9)

MMF: Mycophenolate mofetil; IBD: Inflammatory bowel disease.

Table 3 Abnormal histological findings by mycophenolate mofetil indication

	Solid organ transplant (n)	Autoimmune (n)	Blood disorder (n)	Total (n)
MMF colitis	10	1	0	11
Graft vs host disease	0	0	4	4
Nonspecific colitis	11	0	1	12
Other	3 (hyperplastic), 1 (lymphoid aggregate), 1 (kayexalate), 1 (ischemic), 1 (amyloid)	1 (IBD), 1 (lymphoid aggregate), 1 (hyperplastic)	1 (AML), 1 (reactive)	12

MMF: Mycophenolate mofetil; IBD: Inflammatory bowel disease.